MTOR and non-small cell lung carcinoma: Additionally, increased activation of ERK1/2, mTOR, and S6, as well as increased expression and activation of FGFR1, were all demonstrated in palbociclib- resistant tumors, confirming findings demonstrated in KRAS-mutant NSCLC cell lines.